CD14 promoter-159 polymorphism is associated with reduced risk of intestinal-type gastric cancer in a Japanese population

Construction of a gastric cancer cell line with stably silenced expression of CD14

AIM: To develop a SGC-7901 cell line with stably silenced expression of CD14 to provide an experimental basis for the study of the pathogenesis of gastric cancer.

METHODS: A CD14-shRNA lentiviral vector was constructed to transfect gastric cancer SGC-7901 cells. RT-PCR and Western blot were used to detect the CD14 mRNA and protein levels in untreated SGC-7901 cells (blank control group), SGC-7901 cells transfected with NC-CD14 shRNA (NC-CD14 shRNA control group) and SGC-7901 cells transfected with the CD14-shRNA lentiviral vector (CD14-shRNA lentiviral vector group).

RESULTS: CD14-shRNA expression vector was successfully constructed and transfected into gastric cancer cells. RT-PCR showed that the Ct value for the CD14-shRNA lentiviral vector group was significantly higher than those for the NC-CD14 shRNA control group and blank control group (P = 0.000; P < 0.001), and the 2^Ct value for the CD14-shRNA lentiviral vector group (1±0.08) was significantly lower than those for the NC-CD14 shRNA control group and blank control group (P = 0.0001; P < 0.001). Western blot analysis showed that the relative expression of CD14 protein in the CD14-shRNA lentiviral vector group (0.01) was significantly less than that in the blank control group (1.0) and NC-CD14 shRNA control group (0.83).

CONCLUSION: A CD14-shRNA lentiviral vector has been successfully transfected into gastric cancer SGC-7901 cells, which can inhibit the expression of CD14 mRNA and protein in SGC-7901 cells.